摘要
目的:探讨基质金属蛋白酶(MMP)-3、MMP-9以及金属蛋白酶组织抑制因子(TIMP)-1在系统性红斑狼疮(SLE)发病机制中的作用和意义。方法:采取双抗体夹心ELISA法检测45例SLE患者及30名正常对照者血清MMP-3、MMP-9及TIMP-1水平。结果:①与正常对照者相比,患者血清MMP-3水平明显增高(P<0.01),而血清MMP-9水平明显降低(P<0.01);经糖皮质激素治疗后血清MMP-3水平下降(P<0.01),血清MMP-9水平升高(P<0.01);②SLE患者活动组、抗ds-DNA抗体阳性组、低C3血症者、低血清白蛋白血症者血清MMP-3水平高于对照组(P<0.05),而MMP-9水平低于对照组(P<0.05);SLE患者肾损害组、肺炎组患者血清MMP-3水平高于无上述表现者(P<0.01),而MMP-9水平低于无上述表现者(P<0.01);③血清TIMP-1水平在SlE组与对照组、SLE相关各组间差异均无统计学意义;④SLE患者血清MMP-3水平与SLE疾病活动指数(SLEDAI)呈正相关(P<0.01),MMP-9水平与SIEDAI呈负相关(P<0.01)。结论:MMP-3及MMP-9可能参与SLE发病机制。
Objective: To explore the clinical significance of serum matrix metalloproteinase-3(MMP-3), matrix metallopro-teinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1(TIMP-1) in patients with systemic lupus erythematosus (SLE). Methods: The serum level of MMP-3, MMP-9 and TIMP-1 were measured by ELISA in SLE patients and healthy controls. Results: ① The serum level of MMP-3 in SLE patients was significantly higher as compared with that in healthy controls (P〈 0.01), while the MMP-9 level in SLE patients was decreased (P〈 0.01). After treatment with glucocorticosteroid serum MMP-3 levels decreased markedly (P〈 0.01), but the MMP-9 levels increased (P〈 0.01); ② In the patients with active SLE, decreased C3 levels, hypoalbuminemia or anti-ds-DNA positive, serum MMP-3 levels were higher and MMP-9 were lower than the normal controls (P〈 0.05). MMP-3 levels in patients with renal or pulmonary involvement were respectively higher than those patients without the corresponding involvements (P〈 0.01), and MMP-9 were lower (P〈 0.01); ③Serum TIMP-1 levels did not show significant difference between the SLE patients and healthy controls and within the different SLE groups; ④In SLE patients, a significantly positive correlation betwen MMP-3 levels and SLEDAI scores was found (P 〈 0.01), but serum MMP-9 levels and SLEDAI scores were negatively correlated (P 〈 0.01). Conclution: MMP-3 and MMP-9 are probably involved in the pathogenesis of SLE, which may be used as indicators to moitor disease activity, renal damage, disease progression and improvement in SLE .
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2007年第9期556-558,共3页
Journal of Clinical Dermatology